Cytotheryx vs Adept AI

Side-by-side comparison of AI visibility scores, market position, and capabilities

Cytotheryx

EmergingBioTech

Cell Therapy / Liver Disease

Raised $60M Series A (Jan 2026) led by Ouroboros Capital. Mayo Clinic spinout. Engineered pigs as bio-incubators for human hepatocyte production at scale.

About

Cytotheryx is a Mayo Clinic spinout developing human hepatocytes (liver cells) produced at scale using genetically engineered pigs as bio-incubators. The company raised $60 million in Series A financing in January 2026 led by Ouroboros Capital, with GMP (Good Manufacturing Practice) manufacturing expansion underway to support both its acute liver failure support program and transplant-grade cell therapy pipeline.

Full profile

Adept AI

EmergingAI Infra

AI Agents

Adept AI raised $415M to pioneer computer-use AI agents; its core research and agent team moved to Amazon in 2024 in a landmark talent acquisition while the company continues developing ACT-1 for enterprise automation.

About

Adept AI was founded in 2022 by a team of former OpenAI, DeepMind, and Google Brain researchers to build AI that can take actions on computers — navigating software interfaces, filling forms, and executing multi-step workflows in any application. Its ACT-1 model demonstrated the ability to control web browsers and desktop applications through natural language instructions, pioneering the computer-use agent paradigm that Anthropic later commercialized with Claude's computer use feature.

Full profile

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.